Results 41 to 50 of about 22,516 (228)

Patient selection and composition of the CRPC cohort.

, 2018
Patient selection and composition of the CRPC cohort.
Yukinobu Hamuro (5142812), Stephane Cheung (5142818), Akiko Tsubota (5072102), Jörg Mahlich (3415634), Masahiko Nakayama (5142815)   +4 more
core   +1 more source

Prostate Cancer Patient‐Derived Organoids (PDOs) as Functional Avatars for Antisense Oligonucleotide (ASO)‐Based Personalized Therapy

Advanced Healthcare Materials, EarlyView.
Prostate patient‐derived organoids (PDOs) were established from TURP and biopsy specimens with >90% success and retain key features of their tissues of origin, making them functional avatars for antisense oligonucleotide (ASO) therapy . Transfecting single cells outside the Matrigel matrix and then reconstituting organoids overcomes the 3D delivery ...
Thi Thom Tran, Thi Tu Uyen Phan, Michael Baboudjian, Quang Hieu Duong, Ines Sousa, Thi Thuy Le, Virginie Baylot, Sophie Giusiano, Laurent Daniel, Pauline Brige, Benjamin Guillet, Cyrille Bastide, Carmen Garrido, David Taïeb, Thi Khanh Le, Palma Rocchi   +15 more
wiley   +1 more source

CRPC Membrane-Camouflaged, Biomimetic Nanosystem for Overcoming Castration-Resistant Prostate Cancer by Cellular Vehicle-Aided Tumor Targeting

, 2022
Castration-resistant prostate cancer (CRPC) is the most common malignant tumor of the male urinary system. Nanodrug delivery systems (NDDS) have been widely applied in drug delivery for tumor therapy; however, nanotherapeutics encounter various ...
Kai Lu, Zheng Li, Qiang Hu, Jianfei Sun, Ming Chen   +4 more
core   +1 more source

EP300‐Mediated MTF1‐K218 Lactylation Buffers AR‐Driven Copper Overload to Suppress Cuproptosis in Castration‐Resistant Prostate Cancer

Advanced Science, EarlyView.
Androgen receptor (AR) drives copper accumulation in prostate cancer while inducing MTF1 to buffer copper toxicity. EP300‐mediated lactylation of MTF1 at K218 promotes its nuclear translocation and metallothionein expression, sequestering cytosolic copper and preventing mitochondrial cuproptosis.
Kai Li, Yong Wei, Yongshan Li, Yuxiang Dong, Jiancheng Lv, Mingzhi Yuan, Ao Shen, Fuyang Liu, Yetao Zhang, Youjian Li, Ruixi Yu, Yang Liu, Tong Zhao, Jun Wang, Kai Zhou, Zongyao Fan, Manning Wang, Jun Xu, Mulong Du, Min Gu, Bing Yao, Qingyi Zhu   +21 more
wiley   +1 more source

P300/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC

, 2023
Background N7-methylguanosine (m7G) modification is, a more common epigenetic modification in addition to m6A modification, mainly found in mRNA capsids, mRNA interiors, transfer RNA (tRNA), pri-miRNA, and ribosomal RNA (rRNA). It has been found that m7G
Simeng Wen, Boya Zhang, Xueqiao Chen, Songmao Chen, Shimiao Zhu, Duo Kan, Wenlong Gao, Zhiqun Shang, Yang Li, Yutong Chen, Yuanjie Niu, Chun Wang, Zhao Yang, Mingpeng Zhang   +13 more
core   +1 more source

DEVELOPMENT OF A SOFTWARE CONTROLLER FOR THE AUTOMATED CREATION AND MANAGEMENT OF VIRTUAL RESOURCES FOR RUNNERS

Електроніка та інформаційні технології
The work developed a functional model (prototype) of the controller for the automated creation and management of runners’ virtual computing resources. The analysis of potential technologies for its implementation determined the choice of a combination of
Yu. Korchak, B. Mikh, Yuriy Furgala
doaj   +1 more source

Degrading GPX4 via Biomimetic Nanoparticle‐Mediated In Situ Synthesis of Deep‐Learning‐Designed Binder‐Degron Chimeras for Prostate Cancer Therapy

Advanced Science, EarlyView.
A deep‐learning‐designed binder is fused to a combinatorial degron to create a binder‐degron chimera (bdC) that recruits the CUL2‐RING ubiquitin ligase complex. Encapsulation in a prostate‐cancer‐targeted, CD47‐camouflaged nanocarrier enables tumor‐specific in situ bdC expression, triggering GPX4 degradation and ferroptosis, thereby establishing a ...
Si‐Han Zhang, Ye An, Na Zeng, Mei‐Cheng Liu, Jian‐Xuan Sun, Xi Gong, Jin‐Zhou Xu, Shao‐Gang Wang, Qi‐Dong Xia   +8 more
wiley   +1 more source

ARv7 Is a Transcriptional Repressor in CRPC [PDF]

Cancer Discovery, 2019
Abstract The AR splice variant ARv7 binds to full-length AR and represses transcription of CRPC-suppressive genes.
openaire   +1 more source

Baseline characteristics of 233 CRPC patients based on initial dose of enzalutamide.

, 2021
Baseline characteristics of 233 CRPC patients based on initial dose of enzalutamide.
Jun Miki (11512692), Shin Egawa (10695845), Shotaro Nakanishi (11512689), Takuma Oshiro (10919581), Takahiro Kimura (2344582), Seiichi Saito (10919584), Mitsuyoshi Tamaki (10919578), Tatsuya Shimomura (11512695), Hiroki Yamada (5435), Shunsuke Tsuzuki (11512686), Nozomu Furuta (11512698)   +10 more
core   +1 more source

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)

BMC Urology, 2022
Background Prostate cancer (PCa) is one of the most diagnosed cancers in the world. PCa inevitably progresses to castration-resistant prostate cancer (CRPC) after androgen deprivation therapy treatment, and castration-resistant state means a shorter ...
Yan Li, Hui Shi, Zhenjun Zhao, Minghui Xu   +3 more
doaj   +1 more source